home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

32.54 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

31 32 Next >

Market Whales and Their Recent Bets on VKTX Options ↗

October 22, 2024

Via Benzinga

Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains? ↗

October 22, 2024

Viking Therapeutics (VKTX) set to report Q3 earnings amid high expectations, thanks to promising weight-loss drug candidate. Stock up 240% YTD.

Via Benzinga

Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future ↗

October 17, 2024

Viking recently announced the results of an early-stage clinical trial for VK0214.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 16, 2024

Via Benzinga

Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade ↗

October 14, 2024

The analyst is closely watching MariTide, a potential monthly injection to treat obesity.

Via Investor's Business Daily

Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years ↗

October 10, 2024

Via Benzinga

Viking Therapeutics Unusual Options Activity ↗

October 08, 2024

Via Benzinga

$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today ↗

September 27, 2024

Via Benzinga

Where Will Viking Therapeutics Be in 5 Years? ↗

October 14, 2024

We could be witnessing the birth of a major player in the biotech industry.

Via The Motley Fool

Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics ↗

October 13, 2024

It's hard to go wrong with either company, but one is more appealing.

Via The Motley Fool

The Ultimate Biotech Stock to Buy With $100 Right Now ↗

October 12, 2024

This company is operating in one of today's hottest markets.

Via The Motley Fool

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names ↗

October 11, 2024

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Via Benzinga

Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams ↗

October 09, 2024

Viking Therapeutics' VK0214 Phase 1b trial in X-ALD patients showed significant reductions in VLCFAs and other lipids, while demonstrating safety. Analyst sees potential revenue upside with continued...

Via Benzinga

Viking Therapeutics Unusual Options Activity For September 24 ↗

September 24, 2024

Via Benzinga

What the Options Market Tells Us About Viking Therapeutics ↗

September 17, 2024

Via Benzinga

2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts ↗

October 07, 2024

The investment bank analysts who follow these stocks think they can soar even further, with some caveats.

Via The Motley Fool

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer ↗

October 04, 2024

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

Via Investor's Business Daily

Why Viking Therapeutics Stock Topped the Market Today ↗

September 30, 2024

An analyst waxed bullish on the company's leading pipeline program.

Via The Motley Fool

Is Viking Therapeutics Stock a Buy? ↗

September 29, 2024

The company is in the spotlight for one of its programs, but it's got others that also have promise.

Via The Motley Fool

Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics ↗

September 28, 2024

One of them is performing much better than the other this year.

Via The Motley Fool

Is Viking Therapeutics Ready For Another Surge?

September 27, 2024

Viking Therapeutics' promising weight loss drug could revolutionize the obesity market and propel the company's stock price to new highs.

Via MarketBeat

Why Viking Therapeutics Stock Was So Healthy on Wednesday ↗

September 25, 2024

Hardly for the first time, a pundit following the company waxed bullish on its future.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 23, 2024

Via Benzinga

US Stocks Stall, Gold Updates Record Highs, Tesla Rallies: What's Driving Markets Monday? ↗

September 23, 2024

Wall Street kicked off the week on a cautious note, with major indexes trading relatively flat as investors seek more clarity on the economic and political landscape.

Via Benzinga

Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy? ↗

September 23, 2024

These two stocks could be rivals in the intense GLP-1 space in the future.

Via The Motley Fool

Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today ↗

September 20, 2024

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Via The Motley Fool

Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In' ↗

September 20, 2024

Viking Therapeutics received an Overweight rating and a December 2025 price target of $80 from JPMorgan analysts.

Via Benzinga

Viking Therapeutics Is Having a Year to Remember: Time to Buy?

September 19, 2024

Viking Therapeutics Inc. (NASDAQ: VKTX) has surged 238% year-to-date and 326% over the past year, far outpacing its sector and market.

Via MarketBeat

This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments ↗

September 18, 2024

Terns has a modest market cap of less than $800 million, and its possible upside could be massive.

Via The Motley Fool

Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030 ↗

September 18, 2024

These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.

Via The Motley Fool

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

31 32 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com